Saul Needle

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor

Barbara Hanney, Alfred P. Spada, Glenda E. Bilder et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 152 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype

Christine Y. Ivashchenko, G. C. Teg Pipes, Irina M. Lozinskaya et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2013 · 151 citations

Life Sciences, Cardiology, Cell Biology +15

Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat

Weike Bao, Pu Qin, Saul Needle et al. · Journal of Cardiovascular Pharmacology · 2010 · 100 citations

Medicine, Cardiology, Pharmacology +15

Restenosis Following Angioplasty in the Swine Coronary Artery Is Inhibited By an Orally Active PDGF-Receptor Tyrosine Kinase Inhibitor, RPR101511A

Glenda E. Bilder, Tara Wentz, Robert J. Leadley et al. · Circulation · 1999 · 88 citations

Medicine, Cardiology, Pharmacology +15

RPR 107393, a Potent Squalene Synthase Inhibitor and Orally Effective Cholesterol-Lowering Agent: Comparison with Inhibitors of HMG-CoA Reductase

Dilip Amin, Ruth Z. Rutledge, Saul Needle et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 68 citations

Life Sciences, Biochemistry, Pharmacology +17